Linzess and Immunogenicity

It looks like patients repeatedly treated with Linaclotide have a risk of seeking alternative drug if treatment-related Anti Drug (Linaclotide) Antibody (ADA) is produced resulting in neutralizing the drug.and render it inactive. This is behind this clinical trial as linked below. But SYGP's Trulance is happy to help out at that stage. On a second thought, why physicians shouldn't put patients on Trulance at the first place. Note that Linaclotide is a peptide mimic of endogenous guanylin and uroguanylin, meaning a foreign peptide that can be to recognized by immune system as foreign material that provoke immune rejection where the ADA concern is about. However, Plecanatide (brand name Trulance), Is nearly structurally identical to human uroguanylin. This may explain why Trulance has less side effects and has no concern for ADA issues.

https://clinicaltrials.gov/ct2/show/NCT02590432

 

Doctor just write Amitiza. It works great with practically zero drug to drug interaction and Is covered at 94%.

Enough said!

 

Must be why your growth is anemic. Eventually all the false claims are gonna bite you in the ass, if they haven’t already.

 

The extensive disulfide bridging in LINZESS renders the product more immunogenic than other 14 amino acid peptides.

 

We will know the bad news in March.

 

When is this study going to come out?

 

What is the delay they announced on this. Is the FDA requiring more information?

 

Yes, doesn’t bode well for Linzess. Most likely insurance companies and fda will mandate switches, to much safer Trulance..if Linzess even gets to stay on the market..

 

Keep dreaming Synergy rep.

 

Dear Trulance rep....you are pathetic. You have ZERO scripts in my territory.....you are a copy cat drug that no one is impressed with......I can't keep my docs stocked with Linzess and your samples are crammed on top of mine out of sheer desperation.....loser.

 

The following firms had questions on the IRWD CC this week: Barclay's, Goldman-Sachs, BofA, Morgan-Stanley, Wells Fargo, BTIG, JP Morgan, Credit-Suisse, Mizuho, and Berenberg. Not one of them asked about the immunogenicity trial. No doubt Ram Selvaraju and someone from Oppenheimer will show up on the SGYP CC. Maybe Newman from Canaccord will once again ask if they are going to take the sales force in-house, just to once again prove that he's been asleep ever since he issued his original "buy" rating and $11 price target almost three years ago when the stock was at $7.78. He's been reiterating it regularly ever since.